ANSWER: E

Rationale:

This patient has four identifiable and modifiable contributors to his uncontrolled hypertension, and the correct approach addresses all of them rather than adding another antihypertensive on top of unaddressed reversible causes. First, naproxen must be stopped — regular NSAID use raises BP by 3–5 mmHg, directly blunts lisinopril's antihypertensive and antiproteinuric efficacy, and promotes sodium retention; substituting acetaminophen removes this pharmacological obstacle. Second, OSA evaluation is critical — his symptoms (witnessed apneas, snoring, somnolence, obesity) are highly suggestive; OSA contributes to resistant hypertension through nocturnal sympathetic surges and aldosterone excess in approximately 80% of resistant hypertension cases; CPAP can lower SBP by 2–4 mmHg. Third, amlodipine added to lisinopril addresses the BP combination gap with the evidence-based ACCOMPLISH-supported two-drug strategy. Fourth, switching to an SGLT2 inhibitor (e.g., empagliflozin) addresses glycemic control, provides modest additional BP reduction, promotes weight loss, and is appropriate given his profile.

• Option A: Option A is incorrect because uptitrating lisinopril to 40 mg without removing the naproxen will have limited benefit — NSAIDs blunt RAAS inhibitor efficacy by maintaining prostaglandin-dependent sodium retention; the unaddressed NSAID use and OSA will perpetuate poor BP control regardless of dose escalation.
• Option B: Option B is incorrect because selective COX-2 inhibitors do raise BP and worsen renal prostaglandin-dependent antihypertensive efficacy — the renal prostaglandins that maintain afferent arteriolar tone and promote natriuresis are primarily COX-2 derived in the kidney; celecoxib is not a safer alternative for hypertension management.
• Option C: Option C is incorrect because it addresses only two of the four contributors and omits the critical NSAID issue and glycemic intensification — while OSA evaluation and chlorthalidone are reasonable components, this option is incomplete.
• Option D: Option D is incorrect because spironolactone as the next step before removing the NSAID and assessing OSA is premature — it jumps to a fourth-line agent before addressing readily reversible causes; bariatric surgery, while potentially beneficial, is not the immediate pharmacological priority.

ANSWER: B

Rationale:

Rising microalbuminuria in type 1 diabetes represents early diabetic nephropathy — the transition from hyperfiltration-driven glomerular injury to barrier permeability loss that marks the beginning of the nephropathy-hypertension cycle described in the module. This is a critical pharmacological intervention window: Lewis et al. (1993) demonstrated that captopril, initiated in type 1 diabetic patients with proteinuria and creatinine up to 2.5 mg/dL, reduced the risk of doubling of serum creatinine by 50% and the composite of death, dialysis, or transplantation by 50%, with benefit independent of BP effects. Starting an ACE inhibitor at the microalbuminuria stage — before overt nephropathy develops — captures the maximum window of renoprotective opportunity while simultaneously addressing the mild hypertension.

• Option A: Option A is incorrect because microalbuminuria in type 1 diabetes is not a benign fluctuation — a progressive rise from 22 to 68 mg/g over one year in a patient with new hypertension is a clinically significant signal warranting intervention; the 300 mg/g threshold for initiation misapplies the standard for strongly proteinuric disease to the early intervention opportunity.
• Option C: Option C is incorrect because renal biopsy before RAAS inhibition is not required in type 1 diabetes with classic diabetic nephropathy features — the combination of long-standing type 1 diabetes, progressive microalbuminuria, and new hypertension in the absence of atypical features (hematuria, rapid progression, systemic features) is sufficient to diagnose diabetic nephropathy clinically; biopsy is reserved for atypical presentations.
• Option D: Option D is incorrect because glycemic optimization is important but does not replace antihypertensive RAAS inhibition — DCCT showed that intensive glycemic control reduced microalbuminuria incidence, but in a patient with established and rising microalbuminuria and new hypertension, RAAS inhibition provides additional renoprotection independent of glycemic control.
• Option E: Option E is incorrect because RENAAL enrolled type 2, not type 1, diabetic nephropathy patients — the evidence base for ARBs in type 1 diabetic nephropathy is substantially weaker than for ACE inhibitors (Lewis et al. captopril), and switching the recommendation based on cough risk before the patient has experienced cough is premature.

ANSWER: C

Rationale:

This question integrates two distinct clinical judgments. First, the SGLT2 inhibitor question: empagliflozin's EMPA-REG OUTCOME trial enrolled patients with type 2 diabetes and established CVD — precisely this patient's profile — and demonstrated remarkable cardiovascular benefit (38% reduction in CV death, 35% reduction in HF hospitalization, 39% reduction in renal composite). The absence of an SGLT2 inhibitor in a patient with established ASCVD and type 2 diabetes represents a major gap in guideline-directed therapy. Second, the J-curve concern: in patients with established CAD, diastolic BP below approximately 65–70 mmHg is associated with reduced coronary perfusion pressure (coronary perfusion occurs during diastole and depends on the gradient between aortic diastolic pressure and LVEDP). His current diastolic of 72 mmHg is above this threshold, but adding an SGLT2 inhibitor that modestly lowers BP requires monitoring to ensure diastolic does not fall below the range of concern.

• Option A: Option A is incorrect because SGLT2 inhibitors are not contraindicated at SBP above 140 mmHg — the EMPA-REG OUTCOME and CREDENCE trials enrolled patients with a range of BP values; the BP-lowering effect of 3–5 mmHg systolic actually helps bring BP toward target, not away from it.
• Option B: Option B is incorrect because the J-curve threshold of 60 mmHg is too conservative — clinical evidence and guidelines suggest concern begins at diastolic below 65–70 mmHg in patients with established CAD; dismissing J-curve concern entirely in this patient with prior MI misses an important clinical monitoring consideration.
• Option D: Option D is incorrect because SGLT2 inhibitors do not reduce coronary blood flow through afferent arteriolar constriction — their TGF effect is specific to the renal glomerular microcirculation; there are no SGLT2 transporters in the coronary circulation and no mechanism by which SGLT2 inhibition would reduce coronary blood flow.
• Option E: Option E is incorrect because adding semaglutide rather than an SGLT2 inhibitor is a reasonable alternative but not superior — EMPA-REG OUTCOME provides more specific and robust CV death reduction evidence in established ASCVD than the GLP-1 agonist trials; and the J-curve concern applies equally to any modest BP-lowering intervention including semaglutide.

ANSWER: A

Rationale:

Pregabalin (and gabapentin) are well-known causes of peripheral edema and weight gain through a mechanism involving alpha-2-delta subunit blockade of voltage-gated calcium channels — this affects fluid distribution at the capillary level, causing peripheral edema that contributes to intravascular volume expansion and BP elevation. Peripheral edema from pregabalin is dose-dependent and occurs in 6–17% of patients. The appropriate clinical response is to recognize this as a drug-induced BP elevation, not disease progression — the options include reducing the pregabalin dose, adding a low-dose diuretic to manage the volume component, or considering alternative neuropathic pain treatments (duloxetine, topical agents) that do not cause sodium retention. This is clinically important because adding or intensifying antihypertensives without recognizing pregabalin as the cause leaves the underlying pharmacological mechanism unaddressed.

• Option B: Option B is incorrect because a 14/8 mmHg BP rise over 6 weeks with a temporally associated new medication is not coincidental — pregabalin-related peripheral edema and BP elevation is a recognized and documented adverse effect requiring action, not observation.
• Option C: Option C is incorrect because pregabalin does not stimulate central adrenergic neurons through GABA-analog activity — pregabalin is a calcium channel alpha-2-delta subunit ligand, not a GABA receptor agonist; its mechanism of peripheral edema is peripheral fluid redistribution, not central sympathetic activation; this mechanism is pharmacologically fabricated.
• Option D: Option D is incorrect because pregabalin does not interact with SGLT2 transporters — it binds calcium channel alpha-2-delta subunits, not glucose transporters; no pharmacological interaction between pregabalin and empagliflozin at the SGLT2 transporter exists.
• Option E: Option E is incorrect because pregabalin is not a CYP3A4 inhibitor — pregabalin is renally eliminated without hepatic CYP metabolism and has no significant CYP enzyme interactions; the described amlodipine accumulation mechanism is pharmacologically fabricated.

ANSWER: D

Rationale:

The DPP-4 inhibitor choice does matter clinically in this patient with diabetic CKD and cardiovascular risk factors. Key distinctions: saxagliptin was associated with a significant 27% increase in heart failure hospitalization risk in SAVOR-TIMI 53, despite neutral overall MACE outcomes; alogliptin showed a similar but non-significant HF signal in EXAMINE. These findings restrict saxagliptin and alogliptin use in patients with existing HF or at high risk for HF. Sitagliptin (TECOS) and linagliptin (CARMELINA) showed neutral HF outcomes in their CVOTs. An additional consideration in CKD is dosing: sitagliptin requires dose reduction at eGFR 30–45 (to 50 mg) and below 30 (to 25 mg); linagliptin is uniquely eliminated via biliary/fecal route without renal dose adjustment, making it pharmacokinetically simpler as CKD progresses. For this patient with eGFR 72, sitagliptin at 100 mg is currently appropriate but will require adjustment if CKD progresses; linagliptin would require no such adjustment.

• Option A: Option A is incorrect because irbesartan does not inhibit DPP-4 enzymatic activity — ARBs act on AT1 receptors, not on the DPP-4 enzyme; this interaction is pharmacologically fabricated and no dose reduction of sitagliptin is required based on concurrent irbesartan.
• Option B: Option B is incorrect because saxagliptin does not activate the RAAS through DPP-4 inhibition of ACE — DPP-4 and ACE are different enzymes with different substrates; no pharmacological synergy between DPP-4 inhibitors and ARBs through RAAS modulation has been established in this way.
• Option C: Option C is incorrect because DPP-4 inhibitors are not pharmacologically equivalent in cardiovascular safety — the saxagliptin and alogliptin HF signals are class-specific adverse findings that distinguish these agents from sitagliptin and linagliptin in patients at cardiovascular risk.
• Option E: Option E is incorrect because DPP-4 inhibitors are not contraindicated with ARBs — while DPP-4 does degrade some bradykinin, and DPP-4 inhibitors do raise bradykinin modestly, this does not produce dangerous bradykinin accumulation in combination with ARBs; ARBs do not block bradykinin degradation through ACE (which is the primary bradykinin-degrading pathway); this mechanism mischaracterizes both drug classes.

ANSWER: E

Rationale:

Preconception medication management in this patient requires careful drug-by-drug assessment. Losartan: ARBs (and ACE inhibitors) are absolutely contraindicated in pregnancy — through fetal RAAS-dependent renal development inhibition they cause oligohydramnios (reduced fetal urine output from impaired fetal renal perfusion), skull hypoplasia, limb contractures, pulmonary hypoplasia, and neonatal renal failure. Losartan must be stopped before conception and replaced with a pregnancy-safe antihypertensive — labetalol (alpha and beta blockade), methyldopa (central alpha-2 agonist), or nifedipine ER (DHP CCB) are the established safe options. Empagliflozin: SGLT2 inhibitors are not approved for use in pregnancy — animal studies show renal effects during the period of renal maturation (renal tubular differentiation occurs late in fetal development and postnatally), and although human data are limited, the mechanism of SGLT2 inhibition in maturing fetal kidneys raises safety concerns; regulatory guidance is to stop SGLT2 inhibitors before conception. Amlodipine: DHP CCBs are generally considered safe in pregnancy (nifedipine ER is guideline-recommended); amlodipine can be continued. Metformin: generally considered compatible with pregnancy and is often continued in gestational and pre-existing type 2 diabetes.

• Option A: Option A is incorrect because antihypertensive medications are often needed in pregnancy — untreated severe hypertension carries serious maternal and fetal risks including preeclampsia, stroke, and placental abruption.
• Option B: Option B is incorrect because it correctly identifies losartan as requiring replacement but fails to address empagliflozin, which also requires cessation before conception — an incomplete answer.
• Option C: Option C is incorrect because SGLT2 inhibitors must be stopped before conception — there is no evidence that continuing empagliflozin prevents rebound nephropathy, and the safety concerns in pregnancy mandate cessation.
• Option D: Option D is incorrect because metformin is considered compatible with pregnancy (not the agent that must be stopped), while losartan and empagliflozin both require discontinuation — this option inverts the priorities.

ANSWER: B

Rationale:

This patient exemplifies the clinical challenge of ISH with a constrained diastolic pressure in an elderly diabetic patient. Isolated systolic hypertension in the elderly results from arterial stiffness — the loss of aortic compliance from AGE cross-linking, atherosclerosis, and decades of hypertension means the aorta can no longer buffer cardiac ejection, producing higher systolic peaks and lower diastolic minima (wide pulse pressure). This arterial stiffness-driven ISH is physiologically different from combined systolic-diastolic hypertension in younger patients. The key clinical constraint is that further systolic reduction almost inevitably requires further diastolic reduction, given that most antihypertensives lower both components proportionally. With diastolic at 68 mmHg and a patient with likely subclinical coronary atherosclerosis (age 72, 10+ years of diabetes, hypertension), pushing diastolic below 65 mmHg risks reducing coronary perfusion pressure — coronary blood flow during diastole depends on the gradient between aortic diastolic pressure and LVEDP. Individualizing the target to 140–150 mmHg systolic in this patient is clinically appropriate and guideline-supported for elderly patients where lower targets are not achievable without unacceptable diastolic compromise.

• Option A: Option A is incorrect because RAAS inhibitors do not specifically lower systolic without affecting diastolic in ISH — ramipril and other antihypertensives lower both components; increasing to 20 mg without addressing the diastolic constraint risks worsening the J-curve risk.
• Option C: Option C is incorrect because beta-blockers do not preferentially lower diastolic BP in ISH — they reduce heart rate and cardiac output, which can lower both systolic and diastolic; switching from an effective CCB to a beta-blocker in an elderly patient with ISH is not evidence-based and may worsen glycemic control.
• Option D: Option D is incorrect because chlorthalidone, while effective in ISH (SHEP trial), does not specifically lower systolic without affecting diastolic; it lowers both, and the diastolic constraint applies to thiazide-based therapy equally.
• Option E: Option E is incorrect because hydralazine does not selectively lower diastolic BP — it dilates both arterioles and, to some extent, venules; it would lower both systolic and diastolic and is particularly inappropriate given that it also causes reflex tachycardia, worsening the hemodynamic situation in this patient.

ANSWER: C

Rationale:

Dapagliflozin is strongly indicated in this patient — he has HFrEF where DAPA-HF demonstrated a 26% reduction in the primary composite (worsening HF hospitalization or urgent HF visit plus cardiovascular death) regardless of diabetes status, and he has type 2 diabetic CKD with significant albuminuria where DAPA-CKD demonstrated renal outcome benefit. The dual HF and CKD indications make this a high-priority addition. The clinical challenge is his borderline BP (108/68 mmHg) — at this level, the 3–5 mmHg additional systolic reduction from dapagliflozin's natriuresis, on top of sacubitril/valsartan's vasodilatory effects and existing diuretic therapy, risks symptomatic hypotension. Practical management: consider temporarily reducing the eplerenone dose or the background loop diuretic to create space for dapagliflozin's volume effect; recheck BP, eGFR, and electrolytes within 2 weeks after initiation. The HbA1c of 8.6% also benefits from dapagliflozin's modest glycemic effect.

• Option A: Option A is incorrect because dapagliflozin is specifically approved and guideline-recommended for HFrEF (DAPA-HF) — the preload reduction from natriuresis in HFrEF produces beneficial ventricular unloading, not decompensation; and the claim that SGLT2 inhibitors are only indicated in HFpEF is flatly wrong.
• Option B: Option B is incorrect because symptomatic hypotension from adding dapagliflozin is a monitoring concern, not a contraindication — the approach is to monitor closely and adjust existing medications if needed, not to withhold a therapy with proven mortality benefit in HFrEF.
• Option D: Option D is incorrect because SGLT2 inhibitors do not cause potassium retention — they produce mild kaliuresis through natriuresis; combining dapagliflozin with eplerenone does not double hyperkalemia risk; this combination is used in clinical practice and is not contraindicated.
• Option E: Option E is incorrect because both dapagliflozin (DAPA-HF) and empagliflozin (EMPEROR-Reduced) have proven efficacy in HFrEF — the claim that dapagliflozin evidence applies exclusively to HFpEF is incorrect; both agents have overlapping HFrEF indications.

ANSWER: A

Rationale:

This question tests perioperative medication management for a patient on multiple agents with distinct perioperative safety profiles. Canagliflozin: SGLT2 inhibitors must be stopped at least 3 days (72 hours) before elective surgery — this is the recommendation from ADA, ESC, and major anesthesia societies based on the well-documented risk of euglycemic DKA in the perioperative setting. The mechanism involves surgical fasting (reduced carbohydrate intake lowering insulin secretion), surgical stress hormones (glucagon, cortisol, catecholamines promoting ketogenesis), and continued glucosuria despite low serum glucose — producing metabolic acidosis without hyperglycemia, making eKDA difficult to recognize clinically. Ramipril: ACE inhibitors should be held on the morning of surgery — they blunt the angiotensin II-mediated vasopressor response to anesthesia-induced vasodilation and hemorrhage, producing refractory intraoperative hypotension; restarting when oral intake is established and hemodynamics are stable is standard. Metformin: held on the day of surgery and restarted when oral intake and renal function are confirmed — lactic acidosis risk from hemodynamic instability and reduced renal clearance. Amlodipine: continued — abrupt CCB withdrawal can cause rebound hypertension; no perioperative safety concern mandates cessation.

• Option B: Option B is incorrect because a 5-day complete medication holiday for all four agents is unnecessary and excessive — amlodipine should be continued, and metformin only needs same-day cessation; this approach creates unmanaged BP and glycemic risk.
• Option C: Option C is incorrect because canagliflozin also requires perioperative management — restricting modification only to metformin ignores the well-documented eKDA risk from SGLT2 inhibitors in the surgical setting.
• Option D: Option D is incorrect because switching canagliflozin to a DPP-4 inhibitor is unnecessary — simply stopping canagliflozin 3 days before surgery eliminates the eKDA risk without requiring a drug class switch; DPP-4 inhibitors are not specifically "preferred" perioperative diabetes agents.
• Option E: Option E is incorrect because a 7-day ramipril washout is not required or standard — the guideline recommendation is to hold on the morning of surgery, not 7 days prior; full angiotensin II responsiveness is not the clinical goal, and holding for 7 days would create uncontrolled hypertension preoperatively.

ANSWER: D

Rationale:

This patient has stage 2 hypertension (172/104 mmHg) with severe diabetic nephropathy (UACR 580 mg/g) and requires immediate dual therapy. The pharmacological priorities are clear: RAAS inhibition is the mandatory first-line component — with UACR 580 mg/g, an ACE inhibitor or ARB is not optional; it provides both antiproteinuric renoprotection and BP lowering. Losartan is appropriate at the initiating dose of 50 mg (to be titrated to 100 mg based on creatinine, potassium, and BP response). Amlodipine provides metabolically neutral complementary systemic vasodilation — the ACCOMPLISH paradigm supports the RAAS inhibitor plus CCB combination as superior to RAAS inhibitor plus thiazide for cardiovascular outcomes. Chlorthalidone is deferred: at eGFR 61 approaching stage 3 territory, and with HbA1c already at 9.1%, adding a thiazide diuretic at this stage risks worsening glucose control through hypokalemia-mediated beta cell impairment — the SGLT2 inhibitor planned at 4 weeks will provide natriuretic benefit without the metabolic glucose risk. An SGLT2 inhibitor is the most pharmacologically rational third agent given her diabetic CKD profile and elevated HbA1c. option also defers the SGLT2 inhibitor unnecessarily to 3 months. Option C is correct in choosing ramipril plus amlodipine but deferring glycemic intensification and SGLT2 inhibitor to beyond 4 weeks is suboptimal given the severity of the presentation — option D provides a more complete immediate and short-term plan.

• Option A: Option A is incorrect because deferring RAAS inhibition in a patient with UACR 580 mg/g is pharmacologically unacceptable — the antiproteinuric renoprotective window is being missed; amlodipine plus chlorthalidone provides no intraglomerular pressure reduction.
• Option B: Option B is incorrect because RAAS inhibitor plus chlorthalidone is a reasonable combination but ACCOMPLISH showed ACEi/ARB plus CCB superior to ACEi/ARB plus thiazide; at HbA1c 9.1% with eGFR 61, the glucose-worsening potential of chlorthalidone makes the CCB the preferable add-on; this
• Option E: Option E is incorrect because spironolactone is not the first-line antihypertensive for hypertension in diabetic nephropathy — it lacks the established renoprotective trial evidence of RAAS inhibitors in this setting and should not be used instead of ACEi or ARB as the primary RAAS-targeting agent.

ANSWER: C

Rationale:

Both laboratory abnormalities in this patient are directly attributable to trimethoprim's two well-established pharmacological mechanisms. First, the creatinine rise: trimethoprim is an organic cation that competitively inhibits OCT2 (organic cation transporter 2) in the proximal tubule, blocking tubular secretion of creatinine. Approximately 10–15% of creatinine clearance occurs through tubular secretion — blocking this pathway raises serum creatinine by 0.1–0.4 mg/dL (more in patients with CKD where tubular secretion contributes proportionally more to total creatinine clearance) without any change in true GFR. The creatinine rise from 2.1 to 2.6 mg/dL (a 24% apparent rise) is consistent with this pharmacokinetic artifact in a patient with baseline CKD stage 3b. Second, the hyperkalemia: trimethoprim blocks epithelial sodium channels (ENaC) in the collecting duct collecting tubule through the same mechanism as amiloride — this reduces sodium reabsorption and decreases the electrochemical driving force for potassium excretion, causing potassium retention. In this patient, telmisartan reduces aldosterone-driven ENaC activity through AT1 blockade, finerenone blocks mineralocorticoid receptors directly (reducing aldosterone-mediated ENaC expression), and trimethoprim now blocks ENaC directly — three converging mechanisms of potassium retention producing potassium 5.6 mEq/L.

• Option A: Option A is incorrect because acute interstitial nephritis typically presents with systemic features (fever, rash, eosinophilia, sterile pyuria) and the creatinine rise is real (actual nephron damage), not an OCT2 artifact — the trimethoprim pharmacokinetic explanation is more consistent with the isolated laboratory changes without systemic features; and corticosteroids are not immediately indicated without confirmation of AIN.
• Option B: Option B is incorrect because these changes are within the range that trimethoprim's two direct pharmacological mechanisms can produce, particularly in a patient with CKD and multiple potassium-affecting agents — attributing the findings to a separate AKI without pharmacological explanation first is not the correct clinical interpretation.
• Option D: Option D is incorrect because furosemide does not inhibit trimethoprim's tubular secretion causing drug accumulation and nephrotoxicity — furosemide is an organic anion secreted by OAT1/OAT3, while trimethoprim is an organic cation secreted by OCT2; these are entirely different transporter systems with no competitive interaction.
• Option E: Option E is incorrect because trimethoprim does not suppress renal prostaglandins — it has no COX inhibitory activity; describing it as part of a triple whammy analogous to NSAID combinations is pharmacologically inaccurate.